The biotech has named Jamie Coleman its chief commercial officer ... she served as vice president of brand marketing for Zepbound, during which time she oversaw the accelerated launch of the ...

An ad airing Super Bowl Sunday features “America’s deadliest epidemic,” obesity, and what can be done about it with the use of “affordable” compounded weight loss drugs.

Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and ...

Taking a compounded GLP-1 medication isn’t the same thing as your pharmacy filling a cheaper, generic version of the drug your doctor prescribed.

Hims & Hers offers a copycat of the blockbuster weight-loss drug at a fraction of the cost. But it might be a short-lived ...

and global commercial leadership across therapeutic areas, including most recently serving as Vice President, U.S. Brand Leader for Zepbound®. “We are excited to welcome Jamie to the team as we ...

Pharm Exec’s 20th Annual Pipeline Report examines the emerging drug development trends and surging investments in five ...

Controversy surrounded Hims & Hers’ commercial, called ‘Sick of the System’, in the lead up to America’s biggest sporting ...

Eli Lilly continues to see strong growth coming from its GLP-1 drugs. The company's current 2025 guidance looks conservative.

She joins Kailera from Eli Lilly where she held key roles in brand strategy, consumer marketing, and global commercial leadership across therapeutic areas, including most recently serving as Vice ...

This includes U.S. direct-to-consumer advertising on Zepbound and Mounjaro and U.S. launch activities for Kisunla and Ebglyss. We also increased our commercial investment outside the U.S. to ...